Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Dec 2;10(12):e005543. doi: 10.1136/jitc-2022-005543

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

The antitumor activity of BiTP in murine TNBC models. (A) The representative images EMT-6-hPD-L1 implants in mice receiving antibody treatment. (B) The growth curves of EMT-6-hPD-L1 implants in mice receiving antibody treatment. (C) The weights of EMT-6-hPD-L1 implants in mice receiving antibody treatment. (D) The representative images 4T1-hPD-L1 implants in mice receiving antibody treatment. (E) The growth curves of 4T1-hPD-L1 implants in mice receiving antibody treatment. (F) The weights of 4T1-hPD-L1 implants in mice receiving antibody treatment. (G, H) Survival of tumor-bearing mice receiving antibody treatment. (I, J) Body weight changes of tumor-bearing mice following treatment. (K–M) Rechallenge assays. BALB/c mice were orthotopically inoculated with 10⁵ tumor cells on day 0, and BiTP therapy was initiated on day 4. On day 21, BiTP-cured and treatment-naive mice were inoculated with 10⁵ tumor cells for rechallenge assays. *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001 mean the significant difference compared with BiTP-treated samples. EMT, epithelial-mesenchymal transition; TNBC, triple-negative breast cancer.